Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Tricor Prescribers (US)(?)

Council Members in this Study Group: 104

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Howard Weintraub, MD
Clinical Director
NYU Medical Center

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...

Harold Bays, MD, FACP, President and Medical Director, L-MARC Research CenterHarold Bays, MD, FACP
President and Medical Director
L-MARC Research Center

Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...

Hossein Ardehali, MD, PhD, Assistant Professor, Feinberg School of Medicine, Northwestern UniversityHossein Ardehali, MD, PhD
Assistant Professor
Feinberg School of Medicine, Northwestern University

Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...

Dan Streja, MD
Clinical Professor of Medicine
University of California, Los Angeles

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...

Carlos Dujovne, MD, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CCCarlos Dujovne, MD
Professor of Medicine and Director
OREGON HEALTH & SCIENCE UNIVERSITY - CC

Carlos Dujovne, MD, is an Internist, Gastroenterologist, Clinical Pharmacologist, Certified Clinical Lipidologist, Fr. Prof. of Medicine and Pharmacology, and Director of Clinical Pharmacology's Lipid-Arteriosclerosis Prevention-Treatment Clinic in Dept. of Medicine and Pharmacology at University of...

Joshua Feuer, MD
Owner
Joshua M. Feuer, MD

Joshua Feuer, MD, FACC, is a board certified Cardiologist in solo private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment and reduction....

Charles Glueck, MD, Medical Research Director of Cholesterol Center, Jewish HospitalCharles Glueck, MD
Medical Research Director of Cholesterol Center
Jewish Hospital

Charles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology, and hematology. Dr Glueck and colleagues...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Crestor's results in the Jupiter Study likely to change medical-economic perspectives in statin choices. | 11-13-2008
Author: Carlos Dujovne, MD, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC

1:Crestor is the most potent statin in the market,yet is 3d in sales behind Zocor and Lipitor.2:The efficacy supriority together with its capacity to lower CRP levels led to the highest rate of ASCVD prevention in the shortest period of time evr documented in statin trials.3:The trial in near 18,000...

Mutiple causes for no publications of many reports on FDA approved drugs.Some problems and solutions. | 09-29-2008
Analysis of: Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
Author: Carlos Dujovne, MD, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC

This article is not news for clinical researchers like myself that have performed hundreds of clinical trials in collaboration with the Pharmaceutical Industry. Some of the most common reasons for that are: A)Negative studies are difficult to get published.B)Negative results for the dug of the...

Another reason why government intervention doesn't work | 09-15-2008
Author: GLG Expert Contributor

The Medicare drug system was a political ploy. This just confrims it. The private insurers were unwilling to offer Rx coverage before then because they understood the economics of it.

Statin therapy for children | 08-06-2008
Author: GLG Expert Contributor

The  potential market for treatment of lipids(cholesterol)continues to grow. Recent recommendations regarding potential for treatment of children as young as 8 are controversial, primarily because of the lack of data to demonstrate efficacy in terms of "hard" endpoints(i.e. mortality/MI)vs. morbidity...

Complicated issue | 07-07-2008
Author: GLG Expert Contributor

Many times, nursing homes will call doctors practically demanding some sort of medicne for delusional or combative patients.  They will even suggest medicines by name.  Often, these phone calls occur at 3:00 AM, and the doctor gives a quick yes to give them an answer and get back to sleep....

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Government/Military Hospital or Clinic
  • Other Freestanding Healthcare Facility

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Partner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-05T01:45:24.617